MDGL•benzinga•
Madrigal Pharmaceuticals Reports Preliminary Q4 And FY2024 Rezdiffra (Resmetirom) Net Sales Of $100M-$103M And $177M-$180M, Respectively, With Preliminary Cash Balance Of Approximately $931M, And As Of Year-end 2024, More Than 11,800 Patients On Rezdiffra
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga